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Introduction: Several studies have suggested that anti-diabetic insulin analogue treatment might increase cancer
risk. The aim of this study was to review the postulated association between insulin and insulin analogue treatment
and breast cancer development, and plausible mechanisms.
Method: A systematic literature search was performed on breast cell-line, animal and human studies using the key
words ‘insulin analogue’ and ‘breast neoplasia’ in MEDLINE at PubMed, EMBASE, and ISI Web of Science databases.
A quantitative and qualitative review was performed on the epidemiological data; due to a limited number of
reported estimates, a meta-analysis was performed for glargine only. A comprehensive overview was composed for
in vitro and animal studies. Protein and gene expression was analysed for the cell lines most frequently used in the
included in vitro studies.
Results: In total 16 in vitro, 5 animal, 2 in vivo human and 29 epidemiological papers were included. Insulin AspB10
showed mitogenic properties in vitro and in animal studies. Glargine was the only clinically available insulin
analogue for which an increased proliferative potential was found in breast cancer cell lines. However, the pooled
analysis of 13 epidemiological studies did not show evidence for an association between insulin glargine treatment
and an increased breast cancer risk (HR 1.04; 95 % CI 0.91-1.17; p=0.49) versus no glargine in patients with diabetes
mellitus. It has to be taken into account that the number of animal studies was limited, and epidemiological studies
were underpowered and suffered from methodological limitations.
Conclusion: There is no compelling evidence that any clinically available insulin analogue (Aspart, Determir,
Glargine, Glulisine or Lispro), nor human insulin increases breast cancer risk. Overall, the data suggests that insulin
treatment is not involved in breast tumour initiation, but might induce breast tumour progression by up regulating
mitogenic signalling pathways.* Correspondence: mk.schmidt@nki.nl
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Breast cancer is the most prevalent cancer in women
with 1.67 million new cancer cases diagnosed in 2012
worldwide [1]. Diabetes mellitus (DM) has been associ-
ated with breast cancer [2]. However, it is unknown if
this association is due to the high blood glucose levels of
DM, hyperinsulinaemia, shared risks factors such as
obesity, or side-effects of diabetic treatment.
Exogenous insulin treatment for diabetics includes ani-
mal insulin, human insulin and insulin analogues. Insulin
can act as a growth factor, and it is biologically plausible
that use of exogenous insulin (analogues), could stimulate
neoplastic growth [3]. The initial source of insulin for clin-
ical use in humans was from animal pancreas. Gradually
animal insulin has been almost completely replaced by
modified or biosynthetic human insulin, such as NPH,
Lente or Regular, and insulin analogues. Insulin analogues
have been marketed since 1997 and are different from the
human insulin molecule in that the amino acid sequence
is modified to have an altered pharmacokinetic profile.
These modifications afford greater flexibility in the treat-
ment of diabetic patients. However, structural transform-
ation of human insulin might also result in different
binding affinity towards the insulin-like growth factor-1
(IGF-1) receptor (IGF1R). This may result in increased
mitogenic action of insulin analogues. As each insulin
analogue has different alterations in the amino acid se-
quence, the pharmacologic properties of the analogues are
slightly different. Therefore it could be that various insulin
analogues have different tumour promoting properties.
Glargine is theoretically most likely to have increased
mitogenic action compared to human insulin, as the car-
boxy terminal of the B-chain of glargine has a positive
charge, as is the case with IGF-1.
In 2009, the results of four large-scale epidemiological
studies were published, raising the concern that insulin
analogues, especially insulin glargine, might increase the
risk of cancer [4–8]. Two of these studies suggested that
insulin glargine may be associated with a higher risk of
cancer than treatment with human insulin [5, 8]. Al-
though the results were inconsistent and the authors
stressed the limitations of their studies, this led to an ur-
gent call for more research by the European Association
for the Study of Diabetes [9].
Previous reviews that focussed on in vitro studies con-
sistently reported that in contrast to other commercially
available analogues, glargine has increased binding affin-
ity towards IGF1R. Most studies concluded that glargine
may have increased mitogenic potential in particular at
supra-physiological concentrations [10, 11]. Extrapola-
tion of these results to humans is difficult due to obvious
limitations of in vitro studies, but also due to tissue-
specific biological responses. A focus on a specific can-
cer type could clarify this issue.The published animal studies on insulin analogues and
cancer have not been reviewed so far. In addition, meta-
analyses of epidemiological studies have been inconsist-
ent. One meta-analysis reported an increased relative
risk (RR) of any cancer among insulin (analogue) users
compared to non-insulin-treated diabetics of 1.39 (95 %
CI 1.14, 1.70) [12], while another reported no effect
(RR 1.04; 95 % CI 0.75, 1.45) [13]. Insulin use was not
associated with an increased risk of breast cancer. How-
ever, two [13, 14] out of four meta-analyses [13–16] con-
cluded that the risk of breast cancer was increased
among glargine users compared to non-glargine-users.
Considering that cancer is a heterogeneous disease
with different aetiologies, and breast cancer being the
most common female cancer, we focussed this review on
the association of exogenous insulin (analogue) exposure
and the risk of breast cancer. To study breast cancer risk
in an in vitro, animal and human setting, we made a dis-
tinction between tumour initiation and progression as
most in vivo and in vitro studies can only address
tumour progression. Furthermore, from the literature
review we deducted what is currently known about sig-
nalling pathways involved in insulin-induced tumouri-
genesis. We included all widely prescribed insulin
analogues and insulin AspB10 and included in vitro, ani-
mal, in vivo human and epidemiological studies. To our
knowledge, this is the first review to provide a complete
overview (including in vitro, in vivo and epidemiological
evidence) on whether and how insulin analogues could
affect breast cancer risk in diabetic patients.
Methods
This systematic review is registered at PROSPERO [17]
with the registration number: CRD42012002477 and was
developed according to the preferred reporting items for
systematic reviews and meta-analyses (PRISMA) guide-
lines [18], and with guidance from the Cochrane Collab-
oration handbook [19].
Data sources and searches
A search of MEDLINE at PubMed, EMBASE, and ISI
Web of Science, was performed using key words ‘insulin
(analogue)’ and ‘breast cancer’ (or similar terms) through
July 2014. The full search strategy is described in the
electronic supplementary material (Additional file 1:
ESM 1).
Study selection
Eligible studies had to describe effect measures of exogen-
ous insulin (analogue) use on breast cancer development.
We included studies with direct (tumour incidence, size,
volume, and metastases) or indirect outcomes (cell prolif-
eration, count, and apoptosis, as well as genes and/or
proteins explaining mechanisms of breast cancer tumour
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(MAPK), phosphatidylinositol-4,5-bisphosphate 3-kinase
(PI3K), phosphatase and tensin homolog (PTEN), mech-
anistic target of rapamycin mTOR (p53), that are associ-
ated with breast cancer. Studies were divided into three
categories with the following selection criteria; 1) in vitro
studies of mammary gland cell lines exposed to insulin an-
alogues, in which direct proliferative effect was measured
or pathway activation was monitored; 2) animal studies on
models treated with insulin analogue, in which the mam-
mary gland tumour progression/initiation was measured,
or different insulin analogues were compared for their
activation of mitogenic signalling pathways in mammary
gland tissue, and 3) epidemiological and in vivo studies in
humans, including patients with type 1 or type 2 DM
treated with insulin analogues before breast cancerFig. 1 Flow chart of study identification and study selection process. BC brdiagnosis; cohort and case–control studies as well as ran-
domized controlled trials were included. Only epidemio-
logical studies that presented relative or absolute risk
estimates for breast cancer among insulin users were in-
cluded. Studies that used a non-DM reference population
were excluded. In case of multiple publications on the
same dataset, we included the study with most complete
data. An overview of the study selection is provided in
Fig. 1.
Data extraction
For the in vitro and animal studies information was ex-
tracted on the cell (with insulin receptor (INSR):IGF1R
status) or animal model (species, tumour subtype), study
design (in vitro: assay, starvation method, exposure time,
type and refreshment of medium, and presence ofeast cancer
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time of sampling), the intervention (compounds and
concentration/dose tested) and the study outcome
(mammary tumour formation, mitogenic response, and
pathway activation) (Tables 1 and 2).
For each epidemiological study, information was ex-
tracted on study design and characteristics, i.e., country,
source population, data sources, study period, age group,
matching variables for case–control studies, DM type
and definition, prevalent/incident insulin users, exposure
definition, time of exposure definition, mean duration of
exposure, latency period and covariates (Additional file
1: Table S2, S3c), and risk estimates for each exposure
comparison (Table 3).Data synthesis and analyses
In vitro and animal studies were grouped by type of in-
sulin analogue, and common pathways/mechanisms of
action were extracted and summarized. Plausible path-
ways were suggested based on the strength of the evi-
dence. To substantiate the results of the in vitro studies
included in this systematic review, we created an over-
view of the protein and gene expression in eight com-
monly used mammary (tumour) cell lines of hormone
receptor levels (INSR, IGF1R, ER, PR, HER2, EGFR) and
some proteins essential for insulin-induced downstream
signalling cascades. The methods of these experiments
can be found in Additional file 1: ESM 2.
The exposure comparisons that were examined in the
epidemiological studies were categorized as: 1) use of
any exogenous insulin versus no use of any exogenous
insulin (drug exposure undefined); 2) use of any exogen-
ous insulin versus use of non-insulin anti-diabetic drug
(NIAD) (type of NIAD defined); 3) use of insulin X ver-
sus no use of insulin X. Results were categorized on the
exposure of interest. Data was ordered per risk estimate
(hazard ratio (HR), odds ratio (OR), incidence rate ratio
(IRR)). If a study presented results within the same ex-
posure comparison, but with different definitions of the
exposure of interest (e.g., glargine users or glargine only
users), the group that had most power was included to
calculate the pooled estimate. We set a subjective cutoff
of 10 studies needed for a pooled analysis; hence, this
was only performed for glargine. The pooled estimate
was derived using the random effect model. Pooled ana-
lysis by dose or duration was not feasible, as risk esti-
mates were reported for different exposure comparisons,
exposure definitions (e.g., mean or cumulative dose, dur-
ation since start exposure, or cumulative duration) and
stratification categories. The quality evaluation of the
epidemiological studies focussed on potential selection
bias, information bias, and confounding. The evaluation
process of the bias and power of studies is displayed inAdditional file 1: ESM 3. Data were prepared in Micro-
soft Access 2010 and analysed in Stata version 11.0.
Results
A search in MEDLINE at PubMed, EMBASE, and ISI
Web of Science identified 1,723 unique records (Fig. 1).
After the eligibility assessment, 52 studies on exogenous
insulin (analogue) exposure and breast cancer were in-
cluded, of which there were 16 in vitro, 5 animal, 2 human
in vivo and 29 epidemiological studies (see Additional file
1: ESM 4 for study descriptions).
Evidence of mitogenic/carcinogenic potential
Current evidence of the mitogenic/carcinogenic poten-
tial per insulin (analogue) is described below, highlight-
ing the most important findings displayed in the tables
and figures. In Table 1 an overview is presented of all
in vitro studies in which the mitogenic potency and/or
stimulation of the signalling pathways MAPK and PI3K
upon insulin analogue(s) exposure was determined in a
mammary gland (tumour) cell line [20–35]. Protein ex-
pression of hormone receptors and some downstream
signalling proteins for each cell line are provided in
Additional file 1: Table S1 and Fig. 2. In Table 2 an over-
view is presented of all relevant animal studies [36–40].
Descriptions and characteristics of the epidemiological
studies are presented in Additional file 1: Table S2, S3c
[5, 6, 41–67]. Table 3 lists the overall risk estimates for
breast cancer per insulin analogue in the epidemiological
studies; the corresponding forest plots are presented in
Additional file 1: Figure S1. Results of the meta-analysis
on glargine can be found in Fig. 3. Some studies
provided risk estimates by strata of duration or dose of
exposure (Additional file 1: Table S4). The quality as-
sessment of the epidemiological studies is shown in
Additional file 1: Table S5.
Insulin glargine (M1/M2)
Seven of ten in vitro studies found an increased prolifer-
ative potential of glargine in comparison with human in-
sulin [22, 25, 28, 29, 31, 34, 35] (Table 1). Two studies
found proliferation of glargine as well, but human insu-
lin was not included as a reference compound, therefore
they could not confirm an increased proliferative re-
sponse [32, 33]. One study is difficult to interpret, be-
cause IGF1 did not show increased mitogenic potential
either [24]. Similar to insulin AspB10, glargine has an in-
creased binding affinity towards IGF1R [68]. This recep-
tor is assumed to be responsible for the increased
mitogenic action. Studies including kinase activation as-
says indicate that the PI3K signalling cascade is signifi-
cantly upregulated after glargine stimulation compared
to human insulin stimulation [28, 31, 33, 34]. Two stud-
ies also found the MAPK signalling cascade to be
Table 1 Overview of in vitro studies in breast cancer cell lines on the mitogenic potential of insulin analogues
Author, year Cell line INSR/
IGF1R
Method Starvation Stimulation
time
Refreshment
of medium
Type of
stimulation
medium
Presence
phenol
red
Analogues
tested
Concentrations
tested nM
Mitogenic
response
Sig. PI3K
pathway*
MAPK
pathway*
Milazzo et al.,
1997 [26]
MCF7A 1:4 [3H]Thymidine
incorporation
Yes 24 hrs stim
2 hrs
measure
Yes MEM DME/
F12 + 0.1 %
BSA
Yes AspB10 10 ↑A,B Yes
1:0.8 DNA measurement Yes 3−5 days Yes, every
two days
MEM DME/
F12 + 0.1 %
BSA
Yes AspB10 0.01−10 ↑A,B yes
MCF10B Colony forming assay No 2 weeks Yes, every
two days
MEM DME/
F12 + 2 %
BSA
Yes AspB10 100 ↑A -B Yes
Staiger et al.,
2007 [32]
MCF7A - [3H]Thymidine
incorporation
48hA 20 hrs stim
4 hrs
measure
Yes DME/F12
SFM
No Glargine 10, 50, 100 ↓A No
MCF10B - MTT 24hB 4 days Yes, every
two days
DME/F12
SFM
No Glargine 1, 5, 10, 25 ↑A,B No
No
Liefvendahl
et al., 2008
[24]
MCF7
SKBR-3
1:20 [3H]Thymidine
incorporation
24 hrs 21 hrs stim
3 hrs
measure
No DMEM SFM No Glargine 0.01−100 -
1:1.8
Mayer et al.,
2008 [25]
MCF7A 1:3 Cristal violet cell staining No 4 days No DMEM + 1
% SD-FBS
No Aspart 1.5A,B
Lispro 15A,B
MCF10AB 1:1.2 Glargine 1500C ↑A YesA
Glulisine
T47DC 1:2 Detemir
Shukla et al.,
2009 [31]
MCF7A - Cristal violet cell staining 24 hrs 3 daysA Yes, every 24
hrs
DMEM + 2
% CDFBS
No Aspart 1.5, 15, 150, ↑A No
Lispro 1500 -
2 daysB MEGMB Glargine ↑A yes
Detemir ↓A No
MCF10AB - WB 24 hrs 10 min - DMEM + 2
% CDFBS
No Aspart - -
Lispro - -
MEGMB Glargine Yes ↑A,B ↑A
Detemir Yes ↓A -
Shukla et al.,
2009 [30]
MCF7A - Cristal violet cell staining 24 hrs 3 daysA Yes, every 24
hrs
DMEM + 2
% CDFBS
No Glulisine 1.5, 15, 150,
1500
↓AB No
MCF10AB - 2 daysB MEGM
MMOC/ki67 nuclei
count
No 3 days No Waymouth
medium
SFM
Glulisine 750 ↓ No
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Table 1 Overview of in vitro studies in breast cancer cell lines on the mitogenic potential of insulin analogues (Continued)
WB 24 hrs 10 min - DMEM + 2
% CDFBSA
No Glulisine Yes ↓AB ↓AB
MEGMB
Weinstein
et al., 2010
[35]
MCF7 - Cell counting No 72 hrs Yes every
day
DMEM/SFM Glargine 100 ↑ No
Detemir ↑ No
Oleksiewicz
et al., 2011
[27]
MCF7 - FACS 72 hrs 24−30 hrs No DMEM + 0.1
% FCS
No X10 0.074−2 ↑ Yes
WB 72 hrs 20−40 min No DMEM + 0.1
% FCS
No X10 0.67, 2 Yes ↑ ↑
Teng et al.,
2011 [33]
MCF7A - MTT 24 hours 2 days Yes, every
two days
RPMI + 0.5
% CS-FBS
No Glargine 20−200 ↑A Yes
Yes
WB No 0, 30, 60,
120, 240
min
No RPMI + 0.5
% CS-FBS
No Glargine 100nM ↑A
FACS anti-apoptotic No 48 hrs No RPMI + 0.5
% CS-FBS
Glargine ↑A anti-
Apoptotic
response
Yes
Glendorf
et al., 2012
[21]
HMEC 1:20 [3H]Thymidine
incorporation
No 70 hrs stim
2 hrs
measure
No MEGM ? B10A, 0.0001−1000 ↓
B10R, ↓
X10, ↑
B10Q, ↑
B10E, ↑
B10H, ↓
B10I, ↓
B10F, ↓
B10W, ↓
B10V ↓
Hansen et al.,
2012 [22]
HMECA 1:21 [3H]Thymidine
incorporation
24 hrs 70 hrs stim
2 hrs
measure
No MEGM No Detemir 0.001−1000 ↓A Yes
Glargine ↑A Yes
X10 ↑A Yes
Knudsen
et al., 2012
[23]
MCF7A - [3H]Thymidine
incorporation
2 hrs 24 hrs stim
2 hrs
measure
No DMEM + 0.1
% serum
No S961 0.0001−100 ↑A
Pierre-
Eugene et al.,
2012 [28]
MCF7A - BRET-PIP3 No 45 min No DMEM/F12
+ 5 % FBS
? Aspart -
MDA-
MB-231B
- Lispro -
Glargine Yes ↑A
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Table 1 Overview of in vitro studies in breast cancer cell lines on the mitogenic potential of insulin analogues (Continued)
M1 ↓A
M2 ↓A
Glulisine Yes ↓A
Detemir Yes ↓B
WB 12 5 or 20 min No DMEM/F12 ? Glargine ↑A ↑A
SFM M1 - -
M2 - -
[14C]Thymidine
incorporation
4 hrs 19 hrs stim
6 hrs
measure
No DMEM/F12
SFM
? Glargine 0.01−1000 ↑A
M1 -
M2 -
Gallagher
et al., 2013
[20]
MET1 WB 1 hr 10 min No DMEM + 0.1
% BSA
X10 10 ↑ Yes
MVT1
Ter Braak
et al., 2014
[34]
MCF7
IGF1RA
1:25 WB 30 min No RPMI + 5 %
CDFBS
No Aspart 10, 33, 100 - -
MCF7
INSRB
1:0.02 Lispro Yes ↑A -
MCF7
INSRC
1:0.07 Glargine ↑A ↑ABC
M1 - -
M2 - -
Glulisine - -
Detemir Yes ↓AB C ↓ABC
X10 Yes ↑A ↑ABC
SRB 24 hrs 4 days Yes RPMI + 5 %
CDFBS
No Aspart 0.01−100 -
Lispro -
Glargine ↑ Yes
M1 -
M2 -
Glulisine -
Detemir ↓ Yes
X10 ↑ Yes
Sciacca et al.,
2014 [29]
MCF7A 1:6 BRDU incorporation 24 hrs 12 hrs, 6
hrs
measure
No MEM SFM ? Aspart 5 nM ↓A –B,C,D
MDA-
MB-
1:2 Lispro (only detemir -A,C,D ↑B YesB
157B Glargine at 19 nM) -A,C,D ↑B YesB
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Table 1 Overview of in vitro studies in breast cancer cell lines on the mitogenic potential of insulin analogues (Continued)
MDA-
MB-468C
1:0.2 M1 -A,B,D ↓C
T47DD 1:8 M2 ↑A -B,D ↓C
Glulisine -A,C,D ↑B YesB
Detemir -A,C,D ↑B YesB
X10 ↑A,B –c,D YesB
Collagen invasion assay
(Boyden chamber
technique)
No 18 hrs No MEM SFM ? Aspart -A,D, ↑B,C
Lispro -A,D ↑B,C
Glargine ↑A,B,C ↓D
M1 ↑A,C –B,D
M2 -A,D ↑B,C
Glulisine ↓A,D ↑B,C
Detemir ↑A,B,C,D
X10 ↑A,B,C,D
A/BOften studies used multiple cell lines. A, B, C, D Specific cell line for cell-line-specific conclusions. *Some studies used a specific experimental setup that allowed discrimination between the involvement of different
pathways. For all these studies the p-ERK and p-AKT served as biomarker for activation of mitogen-activated protein kinase (MAPK) or phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), respectively. IGF1R insulin-
like growth factor-1 receptor, BRDU 5-Bromo-2’-deoxyuridine, RPMI Roswell Park Memorial Institute medium, MTT Microculture Tetrazolium proliferation Assay, WB Western Blot, BRET-PIP Bioluminescence Resonance
Energy Transfer assay in which the phophatidylinositol-3 phosphate (PIP(3)) production was monitored, SRB SulfoRhodamine B proliferation assay, MEGM Mammary Epithelial Cell Growth Medium, MEM Minimum
Essential Medium, SFM Serum Free Medium, CDFBS Charcoal-Dextran-Treated Fetal Bovine Serum, Sig Significant.
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Table 2 Overview of in vivo studies in animals on the correlation of insulin analogues and breast cancer
Author, year Model Number of
animals per
treatment
group
Tissues
analysed
Time points
sampling
Analogues
tested
Dose
tested
nM
Method Proteins
analysed
Carcinogenic
potential
Sig. Tumour characteristics
Stammberger et al.,
2002 [37] (re-
evaluation in 2012)
[38]
Sprague–Dawley rats
and Wistar rats and
NMRI mice
5−30 No further
tumour
characterisation
Follow up of 2
years
Glargine 2, 5,
12.5
IU/Kg
Spontaneous
mammary gland
tumour formation
upon treatment
- MG adenoma,
fibroadenoma,
adenocarcinoma
Gallagher et al.,
2012 [36]
Orthotopic mammary
tumour weight and
hyperinsulinaemic MKR
mice
3−4 Mammary
gland
0−25 days AspB10 12.5
IU/kg
Tumour volume
measurement
↑ Yes
Lung
metastasis
2x/day Counting lung
metastases
↑ No
WB receptor activation p-INSR ↑ Yes
p-IGF1R
p-Akt ↑ Yes
p-Erk -
Tennagels et al.,
2013 [39]
Female Sprague–Dawley
rats
3−4 Mammary
gland
60 min Glargine 12.5,
U/kg
WB kinase activation p-INSR -
AspB10 p-IGF1R ↑ Yes
Ter Braak et al.,
2015 [40]
p53R270H/+WAPCre FVB
mice
40 Mammary
gland tumors
Chronic
exposure till
MG tumor
development
Glargine 12.5-
15 IU/
kg
Tumour latency time ↑ No Majority aggressive
EMT no correlation
pathology and
treatment
AspB10 150-
200
IU/kg
↑ Yes
WB protein expression
profiling
INSR
IGF1R,
Erk,
p-Erk, ↑ Yes
Akt,
p-Akt, ↑ Yes
EGFR,
ER,
E-cad,
N-cad,
Her2
IGF1R insulin-like growth factor-1 receptor, EGFR epidermal growth factor receptor, ERK extracellular signal-related kinase, ER oestrogen receptor, E-cad E-cadherin, N-cad N-cadherin, Her2 human epithermal growth
factor receptor 2
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Table 3 Relative risk estimations for breast cancer among insulin treatment groups and the evaluation of bias and power of the studies
Author, year Exposure of interest Exposure comparison
group
Cases/controls*** or cases/person-
years**** in exposure group (number)
Cases/controls*** or cases/person-
years****in comparison group (number)
Risk
Ratio**
95 %
CI
Risk of
bias
Power
Any insulin-no insulin:
hazard ratio
Carstensen et al.,
2012 [43]
Insulin users No insulin users 248/102,500 2,118/627,100 0.96 0.84,
1.09
Moderate Adequate
Ferrara et al., 2011
[48]
Insulin users No insulin users NR NR 1.0 0.9,
1.2
Moderate Adequate
Neumann et al., 2012
[60]
Insulin users No insulin users NR/NR* NR/NR* 0.86 0.81,
0.91
High Adequate
Onitilo et al., 2014
[61]
Insulin users No insulin users NR/NR* NR/NR* 0.84 0.58,
1.23
High Too low
Any insulin-no insulin:
odds ratio
Bodmer et al., 2010a
[41]
Insulin users No insulin users 43/131 262/1,022 NE NE High Too low
Cleveland et al., 2012
[45]
Insulin users No insulin users 20/16 50/49 1.15 0.40,
3.40
High Too low
Any insulin-NIAD:
hazard ratio
Currie et al., 2009a [6] Insulin users Metformin only NR/12,640* NR/34,847* 1.07 0.79,
1.44
Moderate Too low
Redaniel et al., 2012a
[62]
Insulin and NIAD
users
Sulfonylurea only users 33/8,233.8 93/27,308.2 1.23 0.63,
2.38
Low Too low
Redaniel et al., 2012b
[62]
Insulin only users Sulfonylurea only users 8/2,247.3 93/27,308.2 1.67 0.70,
3.99
Low Too low
Vallarino et al.,
2013****** [67]
Pioglitzone users,
not using insulin
Insulin users, not using
pioglitazone
181/29,721 113/13,680 0.85 0.67,
1.08
High Low
Any insulin-NIAD:
odds ratio
Hsieh et al., 2012 [53] Insulin only users Metformin only users 5/NR 19/NR 1.63 0.60,
4.40
High Too low
Koro et al., 2007a [54] Insulin and NIAD
users
TZD users 13/52 83/449 0.71 0.36,
1.37
High Too low
Koro et al., 2007b [54] Insulin only users TZD users 9/62 83/449 1.27 0.61,
2.67
High Too low
Glargine-no glargine:
hazard ratio
Bordeleau et al.,
2014***** [42]
Glargine users Standard care, not
using glargine
28/11,620* 28/12,845* 1.15 0.67,
1.97
Low Too low
Glargine users 4/4,711 6/4,524 0.62 Moderate Too low
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Table 3 Relative risk estimations for breast cancer among insulin treatment groups and the evaluation of bias and power of the studies (Continued)
Home and
Lagarenne, 2009*****
[52]
Any anti-diabetic drug,
NPH in 20 studies
0.17,
2.18
Rosenstock et al.,
2009 [63]
Glargine users NPH users 3/2,144 5/2,096 0.90 0.64,
1.26
Low Too low
Chang et al.,
2011***** [44]
Glargine users,
not using int-/
long-acting HI
Non-glargine int/long-
acting HI users
6/6,558.8* 65/47,724.6* 0.53 0.21,
1.31
Moderate Too low
Colhoun et al., 2009a
[5]
Glargine plus
non-glargine
insulin
users
Non-glargine
insulin users
0/NR 29/9,667* NE NE High Too low
Colhoun et al.,
2009b***** [5]
Glargine only
users
Non-glargine
insulin users
6/1,200* 29/9,667* 1.47 0.59,
3.64
High Too low
Currie et al.,
2009b***** [6]
Glargine users Non-glargine
insulin users
10/2,245* 38/8,102* 0.86 0.42,
1.75
Moderate Too low
Fagot et al.,
2013a***** [47]
Glargine users Other int-/
long-acting
insulin only
users
114/42,129* 40/14,082* 1.08 0.72,
1.62
High Too low
Habel et al.,
2013a**** * [51]
Glargine users NPH insulin users 52/10,614.8 217/60,868.1 1.3 1.0,
1.8
Moderate Too low
Habel et al., 2013b
[51]
Glargine only
users
NPH insulin users 33/6,402.4 217/60,868.1 1.3 0.9,
2.0
Moderate Too low
Habel et al., 2013c
[51]
Glargine and
NPH insulin
users
NPH insulin users 19/4,212.5 217/60,868.1 1.3 0.8,
2.0
Moderate Too low
Kostev et al.,
2012a***** [55]
Glargine users NPH insulin users NR NR 0.93 0.68,
1.27
High Too low
Lind et al., 2012a*****
[56]
Glargine users Non-glargine
users
19/7,019.4 96/48,889.6* 1.54 0.90,
2.67
Moderate Too low
Morden et al., 2011a
[59]
Glargine plus
non-glargine
insulin users
Non-glargine
insulin users
102/18,889* 333/65,294* 1.08 0.86,
1.36
High Low
Morden et al.,
2011b***** [59]
Glargine only
users
Non-glargine
insulin users
118/21,071* 333/65,294* 1.03 0.83,
1.29
High Low
Ruiter et al.,
2012a***** [64]
Glargine only
users
Human insulin
only users
11/6,875* NR; IR=2.28* 1.65 1.10,
2.47
Moderate Too low
Sturmer et al., 2013a
**** [65]
Glargine users NPH users 103/26,277 19/5,885 1.07 0.65,
1.75
Moderate Too low
Suissa et al.,
2011a***** [66]
Glargine users Non-glargine
insulin users
18/6,094 60/12,262 0.8 0.3,
2.1
Moderate Too low
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Table 3 Relative risk estimations for breast cancer among insulin treatment groups and the evaluation of bias and power of the studies (Continued)
Pooled hazard ratio Glargine No glargine 1.04 0.91,
1.17
Glargine-no glargine:
incidence rate ratio
Ljung et al., 2011a
[57]
Glargine plus
non-glargine
insulin users
Non-glargine
insulin users
59/25,033 283/101,419 1.04 0.77,
1.41
High Low
Ljung et al., 2011b
[57]
Glargine only
users
Non-glargine insulin
users
31/7,302 283/101,419 1.58 1.09,
2.29
High Too low
Glargine-no glargine:
odds ratio
Grimaldi-Bensouda
et al., 2013a [49]
Glargine users Non-glargine users 78/287 697/2,763* 1.04 0.76,
1.44
Low Borderline
Grimaldi-Bensouda
et al., 2013b [49]
Glargine users Non-glargine insulin
users
74/203 70/207 0.96 0.61,
1.53
Low Too low
Grimaldi-Bensouda
et al., 2013c [49]
Glargine users Human
insulin users
NR NR 1.29 0.78,
2.13
Low NE
Grimaldi-Bensouda
et al., 2013d [49]
Glargine users Aspart users NR NR 1.10 0.64,
1.89
Low NE
Grimaldi-Bensouda
et al., 2013e [49]
Glargine users Lispro users NR NR 0.85 0.48,
1.50
Low NE
Mannucci et al.,
2010a [58]
Glargine users Non-glargine
insulin users
NR NR NE NE High Too low
Determir-no
determir: hazard
ratio
Fagot et al., 2013b
[47]
Determir users Other int-/
long-acting
insulin only users
38/12,806* 116/43,131* 1.08 0.72,
1.62
High Too low
Kostev et al., 2012b
[55]
Detemir users NPH insulin users NR/789 NR/4,206 1.17 0.66,
2.06
High Too low
Determir-no
determir: incidence
rate ratio
Dejgaard et al., 2009a
[46]
Determir users NPH users 1/2,252 0/1,420 NE NE Low Too low
Dejgaard et al., 2009b
[46]
Determir users Glargine users 1/917 3/628 NR NR Low Too low
Aspart-no aspart:
odds ratio
Grimaldi-Bensouda
et al., 2013f [55]
Aspart users Non-aspart users 54/241 721/2,809* 0.95 0.64,
1.40
Low Borderline
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Table 3 Relative risk estimations for breast cancer among insulin treatment groups and the evaluation of bias and power of the studies (Continued)
Lispro-no lispro:
odds ratio
Grimaldi-Bensouda
et al., 2013g [49]
Lispro users Non-lispro users 46/133 729/2,917* 1.23 0.79,
1.92
Low Borderline
Human insulin-no
human insulin:
hazard ratio
Fagot et al., 2013c
[47]
Basal human
insulin users
Other int-/
long-acting
insulin only
users
15/5,813* 139/50,948* 1.03 0.56,
1.88
High Too low
Gu et al., 2013 [50] Human insulin
users
No insulin users 4/6,188* 14/10,435* 0.33 0.10,
1.13
Moderate Too low
Ruiter et al., 2012b
[64]
Non-glargine
insulin users
Human insulin
only users
31/15,578* NR; IR=2.28* 0.99 0.81,
1.20
Moderate Too low
Human insulin-no
human insulin:
odds ratio
Grimaldi-Bensouda
et al., 2013h [49]
Human insulin users Non-human
insulin users
59/260 716/2,790* 0.81 0.55,
1.20
Low Borderline
Bold values are significantly different. *Calculated using data provided (if not indicated directly these were taken from the table in the paper). **Risk estimates are adjusted for covariates as stated in Additional file 1:
Table S3. Covariates used in the various analyses are the same within one study. ***Case–control studies. ****Cohort studies or randomized clinical trials. *****Included in meta-analysis. ******The exposure of interest is
the exposure comparison group in this analysis. Studies are first ordered by type of exposure and then by type of risk estimate. Note: Hiesh 2012 is a cohort study but provided odds ratio estimates in the paper.
Names of exposure groups are defined by the authors of the study. Several papers showed multiple risk estimates for the same exposure with different analytical approaches. For each study and exposure, the results
from the least biased or best performed analyses are shown; showing hazard ratios, incidence rate ratios or odds ratios as applicable. Different exposure comparisons within one study are indicated by a,b,c etc. We
choose to include the risk estimate that gave (in order of importance): 1) estimates for incident users was preferred over estimates for prevalent users; 2) as-treated analysis (during study period/follow up) was pre-
ferred over intention-to-treat analysis (during fixed period/at baseline); 3) estimates with the longest latency period were preferred. Estimates from statistical models adjusted for covariates were preferred over crude
estimate. NR not reported, NE not estimated, HI human insulin, TZD Thiazolidinedione, NIAD non-insulin anti-diabetic drug, NPH Neutral Protamine Hagedorn, Int intermediate.
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INSR- β
IGF1R- β
p-IGF1R/p-INSR
Her2
EGFR
ER
PR
IRS-1
IRS-2
Erk
p-Erk
Akt
p-Akt
Ki67
E-Cadherin
N-Cadherin
Vimentin
α-tubulin
β-actin
GAPDH
Fig. 2 Protein expression profiling of eight commonly used human
breast cell lines. Receptor levels and signalling molecules downstream
of the insulin receptor/insulin-like growth factor-1 receptor (INSR/IGF1R)
signalling pathway have been quantified. Furthermore some breast
cancer subtype markers have been used to further characterize
these cell lines that are commonly used in the research articles
discussed in this review. Her2 human epidermal growth factor
receptor 2, EGFR epidermal growth factor receptor, ER oestrogen
receptor, PR progesterone receptor, Erk extracellular signal-related
kinase, GAPDH glyceraldehyde-3-phosphate dehydrogenase
IRS Insulin Receptor Substrate
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mitogenic potential is as yet unknown because glargine
is rapidly metabolised in vivo into two metabolically
active compounds, M1 and M2 [69, 70]. These metabolites
possess low mitogenic signalling [28, 34].
In a 2-year follow up study, wild-type Sprague–Dawley
rats, Wistar rats, and NMRI mice have been used to test
the effect of chronic glargine injections compared to the
insulin NPH injections; no difference in tumour-free
survival was observed [37, 38] (Table 2). In contrast, a
recent study revealed a (non-significant) decrease intumour latency time after a similar chronic exposure to
glargine; tumour multiplicity or metastases were not af-
fected [40]. Glargine injections induced no increased re-
ceptor activation response in the mammary glands of
Sprague–Dawley rats [39].
Three randomized clinical trials (RCT) that investi-
gated breast cancer risk among glargine users compared
to non-glargine users [42, 52, 63] did not show signifi-
cant differences (Table 3). Most case–control and cohort
studies showed a non-significant increased risk. Only
two observational studies [57, 64] showed a statistically
significant increased risk of breast cancer with an IRR of
1.58 (95 % CI 1.09, 2.29) and HR of 1.65 (95 % CI 1.10,
2.47), respectively. Both studies included glargine-only
users and compared them to non-glargine insulin users
[57] and human-insulin-only users [64]. As the glargine
studies did not show statistically significant heterogen-
eity (I2 = 0.0 %; p >0.05) a meta-analysis was performed.
From 13 studies the pooled HR for glargine vs no use of
glargine was 1.04 (95 % CI 0.91, 1.17; p = 0.49) (Fig. 3
and Table 3), showing no evidence for an association be-
tween insulin glargine treatment and increased incidence
of breast cancer.
Insulin detemir
Like glargine, detemir is a long-acting insulin analogue. In
general, it is assumed that detemir has a lower mitogenic
potential compared to human insulin [22, 28, 31, 34], but
in a number of in vitro studies similar proliferation or
even increased proliferation of determir has been observed
[25, 29, 35] (Table 1). The binding characteristics of dete-
mir to albumin are different among species. In almost all
in vitro studies BSA or FBS is added to the stimulation
medium. Interpretation of these mitogenicity studies is
difficult because it is not yet known how the bovine albu-
min interacts with detemir compared to human albumin
[11]. For the same reason it is not surprising that no
chronic animal studies have been conducted with insulin
detemir. Only three epidemiological studies have been
performed, one RCT [46] and two cohort studies [47, 55];
none found an association with breast cancer develop-
ment (Table 3).
Insulin aspart, glulisine and lispro
Compared to glargine and detemir, the insulin ana-
logues aspart, glulisine and lispro are less well evaluated
for mitogenic potential; no increased mitogenic action
was found in four in vitro studies [25, 28, 30, 34]
(Table 1). Only one in vitro study suggested a small
non-significant proliferative increase of aspart com-
pared to human insulin [31]. Another in vitro study
found the mitogenic potential of glulisine to be signifi-
cantly lower than human insulin [30]. Evidence that lis-
pro and glulisine had increased proliferative potential
Fig. 3 Forest plot of reported hazard ratios for risk of breast cancer among insulin glargine users. RCT randomized controlled trial
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the tested cell lines (MDA-MB-157 and MDA-MB-468)
[29]. We previously found that the PI3K signalling
cascade is significantly more upregulated after lispro
treatment than human insulin stimulation only in the
IGF1R overexpressing MCF7 cell line [34]. Similar to
the in vitro data, the epidemiological data on these
short-acting insulin analogues is scarce. Just one study
reports ORs for aspart and lispro of 0.95 (95 % CI 0.64,
1.40) and 1.23 (95 % CI 0.79, 1.92), respectively [49]
(Table 3).Human insulin
In vitro studies showed that treatment of diabetics with
human insulin has low mitogenic potential (Table 1).
From the in vivo studies it can be concluded that human
insulin is not carcinogenic as the number of tumours
that developed in the human-insulin-treated group was
similar to the vehicle-injected group (Table 2). Only
three epidemiological studies explored the effect of
human insulin as the exposure of interest on the risk of
breast cancer. Two of these studies compared human
insulin users with insulin analogue users [47, 49] and
found no significant difference in breast cancer risk
(Table 3). The other study compared human insulinusers with diabetics not treated with insulin and re-
ported a HR of 0.33 with a relatively wide 95 % CI of
0.10, 1.13 [50]. This study was under powered.
Human insulin, especially NPH, was often used as ex-
posure comparison group in the studies that investigated
risk of breast cancer related to insulin analogue use. Most
of these studies did not report significant differences in
the risk of breast cancer, as mentioned previously.Insulin AspB10
The increased carcinogenic effect of insulin AspB10 had
already been discovered in 1992 [71]. Since then this in-
sulin analogue has been used in many in vitro studies as
a reference compound with a strong carcinogenic poten-
tial. In proliferation studies AspB10 was highly mito-
genic compared to human insulin, irrespective of the
cell line used [21, 22, 26, 27, 29, 34] (Table 1). Most
studies indicated that AspB10 induces proliferation by
increased IGF1R signalling, but there are indications that
the INSR is also involved because increased proliferation
was not fully blocked when using a specific IGF1R in-
hibitor [26]. One study used two murine mammary
tumour cell lines, both expressing INSR and IGF1R.
These cell lines were stimulated with AspB10 and only
activation of INSR and not IGF1R was observed [20]. In
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pancy time of this analogue towards the INSR results in
sustained activation of this receptor and subsequently
increased mitogenic potency [22]. With a collagen inva-
sion assay it was determined in several breast cancer cell
lines that AspB10 has an increased invasive capacity
compared to human insulin [29]. In a very elaborate kin-
ase/inhibitor study it was found that multiple core ki-
nases are involved in the mitogenic action of AspB10,
because phosphorylation of AKT, p70S6K, S6, and 4E-
BP1 was found to be increased compared to human in-
sulin exposure [27].
In animal studies, AspB10 was found to have dose-
dependent increased carcinogenic potential [71] (Table 2).
Xenograft rodent models with injected mammary gland
tumour cell lines were treated with either human insulin
or AspB10. Tumours were significantly bigger after the
AspB10 injections and, although not significant, more
lung metastases were found in this treatment group.
Strong upregulation of p-AKT has been observed on kin-
ase activation analysis of these tumours, indicating that
the carcinogenic effects of AspB10 might be a direct effect
from a PI3K response [20]. A very recent study used a
p53R270H/+WAPCre mouse model, which develops spon-
taneous human relevant mammary gland tumours within
70 weeks, to show that chronic exposure to AspB10 sig-
nificantly decreases the tumour latency time. A detailed
protein expression analysis showed that tumours induced
by AspB10 or IGF1 have a distinct expression pattern
compared to tumours from insulin- or vehicle-treated
mice; both the PI3K and the MAPK were found to be sig-
nificantly upregulated after AspB10 and IGF1 treatment
[40]. A different study focussed on the short term mito-
genic effects of AspB10 and found significantly stronger
receptor activation in the mammary glands of Sprague–
Dawley rats one hour after AspB10 injections compared
to human insulin treatment [39]. As insulin AspB10 has
been shown to have mitogenic properties in in vitro and
animal studies, this drug has never been available to
humans.
Insulin (analogue) users versus non-insulin users or NIAD
users
In the epidemiological studies, the risk of breast cancer
mostly showed non-significant decreased associations
with insulin use vs non-insulin use (drug exposure un-
defined) (Table 3). These studies did not distinguish be-
tween insulin analogues and human insulin. In contrast,
most studies that compared insulin users with NIAD
users (irrespective of the type of NIAD used) showed
non-significant increased associations with risk of breast
cancer. Only one study comparing insulin users versus
non-insulin-users showed a statistically significant de-
creased risk of breast cancer (HR 0.86; 95 % CI 0.81,0.91) in patients with type 2 diabetes [60]. However, we
judge this study to be biased because the risk estimates
were not adjusted for important risk factors for breast
cancer and DM, immortal time bias might be present,
and no data on duration of exposure were available.
Exposure categories (insulin use-no insulin use and insu-
lin use-NIAD only use) are hard to define and compare,
because many patients with type 2 diabetes are using
insulin (analogues) simultaneous with NIADs. Most
studies that are included in this review investigated com-
bined categories of exposure to insulin (analogues) and
NIADs.
Dose and duration effects in epidemiological studies
No significant differences were found between strata of
duration and risk of breast 5 five years of any insulin
treatment (HR 2.25; 95 % CI 0.72, 6.99) [62]. Among the
glargine users, the study with the longest follow up com-
paring exposure of 4–7 years versus <4 years did not ob-
serve increased breast cancer risk [49]. Another study
revealed that the risk of breast cancer increased in the
first 3 years after the start of insulin glargine use, after
which the risk of breast cancer remained at the same
level [56]. Results of the effect of glargine dose on the
occurrence of breast cancer [47, 49, 56, 58, 59, 64] pro-
duced inconsistent results (Additional file 1: Table S4).
Some studies found significantly increased relative risks
with increasing dose [56, 59, 64], while others did not
[47, 49, 58, 59]; this seems partly dependent on the ex-
posure definition. Only one of the studies investigating
glargine dose used cumulative dose [47]. The results of
one in vivo study in humans indicated that there is al-
most no glargine circulating in plasma regardless of the
dose given. Plasma M1 concentration increased with in-
creasing dose of glargine, but as was mentioned previ-
ously, M1 possesses low mitogenic signalling [70].
Discussion
Limitations of the studies and interpretation of the
findings
In vitro studies
The large variation in published in vitro results can be
explained by differences in study design. For example,
the choice of cell line greatly affects the obtained results
because the responsiveness to growth factors, like insulin
and insulin analogues, may be different from one cell
line to another. Based on the cell line characterisation
(Additional file 1: Table S1), we showed there is a strik-
ing variation in receptor expression of the human cell
lines used.
Different cell lines also have different expression of the
relevant receptors involved in the insulin response. The
MDA-MB-231 cell line has very low expression of
IGF1R. Therefore, the increased mitogenic potential of
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be detected in this cell line [28]. However, using the
MCF7 cell line (which expresses very high levels of
IGF1R) the increased mitogenic potential of this com-
pound became evident [28]. Other cell lines with low or
moderate expression levels of IGF1R are less suitable for a
mitogenic evaluation of insulin analogues. In line with
this, a recent study including four different breast cancer
cell lines (MCF7, MDA-MB-157, MDA-MB-468 and
T47D) found that mitogenicity of growth factors strongly
depends on the cell line that was used [29]. However, the
authors concluded that the INSR/IGF1R status was not
the only explanatory factor. Therefore, we determined the
expression of downstream signalling molecules (Fig 2).
This illustrated that the poor responsiveness in the T47D
and MDA-MB-468 cell lines upon glargine exposure
[25, 29] may be explained by low expression of IRS1
(T47D) or IRS2 (MDA-MB-468), the first downstream
targets of the INSR/IGF1R.
Besides INSR/IGF1R signalling other receptors also
might have a role in insulin (analogue)-induced mitoge-
nicity. Due to insulin-oestrogen receptor/progesterone
receptor (ER/PR) crosstalk the IRS1 and subsequently
the PI3K and MAPK signalling cascades can be upregu-
lated resulting in enhanced proliferation [72]. This ef-
fect might contribute to the increased insulin (analogue)
sensitivity of MCF7, T47D and ZR-75-1 compared to the
triple-negative cell lines (MDA-MB-157, MDA-MB-231,
MDA-MB-468 and MCF10A). Therefore, it is important
to point out that primarily ER-positive or triple-negative
breast cancer cell lines have been used in the included
studies.
The majority of the mitogenicity studies used the
MCF7 cell line [23–35]. It is desirable that future studies
include different cell lines, so that cell-line-specific
effects can be excluded. For translational reasons it is es-
sential that protein expression (and especially receptor
profiles) in benign human mammary gland tissues are
quantified, only in that way we can determine which cell
model has the highest clinical relevance.
Another important quality factor is the starvation
method. For a proper effect of a specific stimulation it
is essential that the target cells are deprived from other
growth factors. Some studies did not starve their cells
prior to the start of the assay [21, 25, 28, 33]; for short-
term assays especially, this might have major conse-
quences. Finally, the use of proper positive and negative
controls is most important for a good quality experiment.
Some studies [32, 33] did not include a positive control
while others lack a negative control [23], thereby making
it impossible to put the results in perspective. Further-
more, one study did include a positive control (IGF1) [24],
but this compound did not show a positive effect, which
questions the sensitivity of their experiments.Animal studies
The type of animal model used plays a major role in the
quality of animal studies. Generally, it is thought that
rats are more sensitive in terms of carcinogenicity to-
wards compounds and have a higher clinical relevance
than mouse models [73]. But there are also major disad-
vantages, like higher costs and the lack of good human-
ized breast cancer rat models. Two studies that used rats
have rather small group sizes, which obviously affects
the power of their studies [37–39]. The doses that were
used in the reviewed animal studies are quite compar-
able to each other and are all thought to be supra-
physiological (i.e., over 50 times the human dose, based
on nmol/kg). In one study a non-equimolar comparison
was made between the different compounds, but doses
had been chosen to induce an equi-pharmacological/
metabolic response [40]. High mortality was observed in
another study, probably due to hypoglycaemia, therefore
the dose was lowered in a later phase of this study [39].
Surprisingly, other studies that used similar doses did
not observe hypoglycaemia [37, 38, 40]. To verify the
sensitivity of the models and techniques it is essential
that the appropriate controls are included. Half of the
included animal studies lacked proper controls. In our
opinion both insulin and IGF1 (and ideally also AspB10)
should always serve as controls to be able to put the ob-
tained results into perspective.
Epidemiological studies
The epidemiological studies included in this review have
many limitations and results are difficult to compare
across studies because the exposure of interest and
exposure comparison groups have been defined differ-
ently. For example, some studies compared glargine-only
users with human-insulin-only users [64], while others
compared glargine users with non-glargine-insulin users
[66]. In this case, the comparator is a mix of several
exposures, which may affect the conclusion about the
effect of certain insulins (analogues). Some studies ex-
amined several definitions for the exposure of interest
and indeed this resulted in slightly different effect esti-
mates [57, 59]. Moreover, it is difficult to disentangle the
effect of insulin and the role of NIADs because most
diabetic patients treated with insulin have prescriptions
of NIADs as well. However, it is important to do so, be-
cause some studies have shown anti-tumour effects of
metformin, the most prescribed NIAD among patients
with type 2 diabetes [74]. Of note, the quality of some of
these metformin studies is doubtful as well.
Inclusion criteria differed largely among studies. For
example, some studies included patients with only one
insulin prescription while others included continuous
users over a period of 6 months. More important, there
was large variation in the definition of time of exposure.
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types at baseline or during a fixed period (intention to
treat), while others determined insulin exposure during
follow up (time-dependently). This may lead to patients
with only one specific insulin prescription during follow
up being falsely classified as continuous users during the
whole period. Cumulative exposure over time, censoring
for discontinuation, or switching and latency period
could affect the results. The uncertainty surrounding the
extent to which a registered prescription dispensed for
an insulin analogue reflects real life use of insulin ana-
logues limits the ability to detect the true effect on the
occurrence of breast cancer. Furthermore, studies vari-
ably included incident and prevalent users of insulin
compromising estimates of association between the dur-
ation of use and breast cancer development.
Other methodological aspects that are important when
interpreting the results of these studies are incorrect and
too short an exposure time (maximum 3.8 years mean
exposure time), reverse causation, confounding by indi-
cation, and residual confounding (Additional file 1: ESM
3). Most studies were based on type 2 DM, and/or did
not specify the type of DM. Risk of bias was classified as
low (for definition see Additional file 1: ESM 3) in only
five studies [42, 46, 49, 62, 63], but the power of these
studies was inadequate (Additional file 1: Table S5). Of
these studies, only two considered breast cancer as a
main outcome [49, 62]. Most risk estimates have wide
CIs, due to lack of power of the study. Two of the three
studies that found significantly different results were
classified as having a high risk of bias [57, 60] or had
lack of power [57, 64]. So far there is not a single very
well-designed study to have investigated insulin treat-
ment and breast cancer risk as the main outcome, with
sufficient power. The included RCTs had limitations too,
such as limited follow up (except for one RCT with a
follow up of 6 years [42]), insufficient power, or cancer
incidence as a secondary outcome [63, 75].
All layers of evidence in perspective
Studies in humans are the gold standard for evaluating
evidence of exposure and disease. The epidemiological
studies reviewed varied in study design and exposure
definition to too large an extent among different insulin
analogues to evaluate their impact on breast cancer risk
estimates. The risk estimates seemed not to be biased by
important confounders, as adjusted and unadjusted risk
estimates only differed slightly. However, unmeasured
confounding may still be present. In addition, the upper
limit of the 95 % CI of the pooled risk estimate of breast
cancer among glargine users was 1.17. This strengthens
our idea that if any, the increased risk of breast cancer
due to currently used insulin (analogues) is likely to be
very small.A distinction should be made between studying
tumour initiation or progression, though in the human
setting it difficult to discern these because of potential
lag time in the detection of cancer. The epidemiological
studies investigated the incidence of primary breast
tumours upon insulin treatment in DM patients. True
tumour initiation in animal studies can only be investi-
gated with long-term exposure in rodents, which are
costly experiments. The animal xenograft models and
in vitro studies of mammary tumour cell lines summa-
rized here investigated tumour progression; e.g., by
evaluation of cell proliferation or upregulation of mito-
genic pathways. All together, the results of this system-
atic review suggest that insulin treatment might be
involved in tumour promotion.
Another issue to be raised is that breast cancer is not
one disease but consists of different subtypes, e.g., ER-
positive or ER-negative cancer with different prognoses.
The promotion of tumour cell growth upon insulin ex-
posure may differ for different breast cancer subtypes.
However, there are very limited human/epidemiological
data from only two studies on the association of tumour
subtypes and insulin (analogues) exposure among dia-
betic patients with breast cancer [49, 76]. More data are
available on the prognosis of diabetic patients with
breast cancer. It has been shown that overall mortality
after breast cancer diagnosis is 25 to 50 % higher in dia-
betic women compared to their non-diabetic counter-
parts [45, 62, 77, 78], even after adjustment for tumour
stage [77, 78]. However, whether this increased mortality
is breast cancer-related or caused by comorbidities re-
lated to DM is not clear. Breast cancer in patients with
DM is often diagnosed at an advanced stage compared
to patients without DM [77–80]. But studies that investi-
gated the association between breast cancer-specific
mortality and diabetes have inconsistent results
[45, 78, 80, 81]. Among patients with type 2 DM, insulin
treatment is associated with a worse cancer outcome and
increased all-cause mortality compared to metformin
treatment [78, 82]. Only one study investigated the effect
of cumulative dose and duration of insulin treatment on
breast-cancer-specific survival, and found lower mortality
from breast cancer [83].
Conclusion
Based on the current epidemiological and animal data
there is no compelling evidence that any clinically avail-
able insulin analogue, or human insulin increases breast
cancer risk. However, animal data were limited and there
is not a single very well-designed epidemiological study
to have investigated insulin treatment and breast cancer
risk as the main outcome, and with sufficient power.
Large randomized clinical trials were negative for
increased breast cancer risk with glargine, but longer
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effects. In vitro studies have shown that only insulin
AspB10 and glargine have increased mitogenic potential
compared to regular human insulin in breast cancer cell
lines. The relevance of this finding for the clinical situation
is unknown because AspB10 is not used in humans and it
has been shown that glargine is rapidly metabolized in vivo
into M1 and M2, metabolites with low mitogenic potential.
Evidence on the potential pathways involved in insulin-
analogue-induced breast cancer mitogenesis is limited.
Unanswered questions and future research
Except for insulin AspB10, which has never been avail-
able to humans, all insulin analogues are still marketed.
Although, there is evidence from in vitro data that insu-
lin glargine has increased mitogenic potential, so far, epi-
demiological studies have not shown evidence for an
association between insulin (analogue) treatment and
breast cancer risk in female diabetic patients. However,
due to a relatively short follow up time in the epidemio-
logical studies, it cannot be excluded that diabetic pa-
tients with pre-neoplastic lesions might be at higher risk
of developing an invasive tumour when given a specific
insulin treatment. Research on this topic is important
but is still largely lacking. Therefore, we are awaiting the
results of ongoing efforts to pool multiple large national
databases from different countries to perform a retro-
spective observational study in humans with a proper
design, enough patients and long follow up. Additionally,
further research into the aetiology of insulin and breast
cancer development is important.
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